

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-14. (Canceled)

15. (Previously Presented) An isolated antibody that binds to a polypeptide having at least 80% amino acid sequence identity to:

- (a) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);
- (b) the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;
- (c) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide;
- (d) an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide;
- (e) a polypeptide encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or
- (f) a polypeptide encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

16. (Previously Presented) An isolated antibody that binds to a polypeptide having:

- (a) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355);
- (b) the amino acid sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

- (c) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), with its associated signal peptide sequence;

(d) an amino acid sequence of an extracellular domain of the polypeptide shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355), lacking its associated signal peptide sequence;

(e) an amino acid sequence encoded by the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355); or

(f) an amino acid sequence encoded by the full-length coding region of the nucleotide sequence shown in any one of Figures 1-6355 (SEQ ID NOS:1-6355).

17. (Previously Presented) The antibody of Claim 15 or 16 which is a monoclonal antibody.

18. (Previously Presented) The antibody of Claim 15 or 16 which is an antibody fragment.

19. (Previously Presented) The antibody of Claim 15 or 16 which is a chimeric or a humanized antibody.

20. (Previously Presented) The antibody of Claim 15 or 16 which is conjugated to a growth inhibitory agent.

21. (Previously Presented) The antibody of Claim 15 or 16 which is conjugated to a cytotoxic agent.

22. (Previously Presented) The antibody of Claim 21, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

Serial No.: 10/529,351

Filed: March 25, 2005

23. (Previously Presented) The antibody of Claim 21, wherein the cytotoxic agent is a toxin.

24. (Previously Presented) The antibody of Claim 23, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

25. (Previously Presented) The antibody of Claim 23, wherein the toxin is a maytansinoid.

26. (Previously Presented) The antibody of Claim 15 or 16 which is produced in bacteria.

27. (Previously Presented) The antibody of Claim 15 or 16 which is produced in CHO cells.

28. (Previously Presented) The antibody of Claim 15 or 16 which induces death of a cell to which it binds.

29. (Previously Presented) The antibody of Claim 15 or 16 which is detectably labeled.

30-184. (Canceled)